Modular transporters for subcellular cell-specific targeting of anti-tumor drugs

BioEssays

Volumn 30, Issue 3, 2008, Pages 278-287

  Sobolev, Alexander S ^a,b  

^a INSTITUTE OF GENE BIOLOGY   (Russian Federation)

^b MOSCOW STATE UNIVERSITY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERMEDIN; EPIDERMAL GROWTH FACTOR; INTERLEUKIN 3; MELANOCORTIN 1 RECEPTOR; RADIOISOTOPE; SOMATOSTATIN RECEPTOR;

ATOMIC FORCE MICROSCOPY; BINDING AFFINITY; CELL KILLING; CELL SPECIFICITY; CELL SURFACE; CELLULAR DISTRIBUTION; CYTOTOXICITY; ENDOCYTOSIS; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; MELANOMA CELL; NONHUMAN; PHOTOSENSITIZATION; PROTEIN EXPRESSION; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL NUCLEUS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOCYTOSIS; HUMANS; HYDROGEN-ION CONCENTRATION; LIGANDS; MICE; MODELS, BIOLOGICAL; MODELS, THEORETICAL; NEOPLASMS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; SUBCELLULAR FRACTIONS;

EID: 40349106008     PISSN: 02659247     EISSN: None     Source Type: Journal    
DOI: 10.1002/bies.20715     Document Type: Review

References (70)

1. Takemura T, Ohta N, Nakajima S, Sakata I. 1989. Critical importance of the triplet lifetime of the photosensitizer in photodynamic therapy of tumors. Photochem Photobiol 50:339-344.
2. Moan J, Berg K. 1991. The photodegradation of porphyrins in cells can be used to estimate the lifetime of singlet oxygen. Photochem Photobiol 53:549-553.
3. Li H, Jacque A, Wang F, Byrnes RW. 1999. Diffusion distances of known iron complexes in model systems. Free Radic Biol Med 26:61-72.
4. Liang H, Shin DS, Lee YE, Nguyen DC, Trang TC, et al. 1998. Subcellular phototoxicity of 5-aminolaevulinic acid (ALA). Lasers Surg Med 22:14-24.
5. Wiseman H, Halliwell B. 1996. Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. Biochem J 313:17-29.
6. 6 enhances its photosensitizing activity. J Biol Chem 272:20328-20331.
7. 6. Int J Cancer 81:734-740.
8. Larson SM, Krenning EP. 2005. A pragmatic perspective on molecular targeted radionuclide therapy. J Nucl Med 46:1S-3S.
9. Zalutsky MR, Vaidyanathan G. 2000. Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha particle therapy. Curr Pharm Design 6:1433-1455.
10. Mulford DA, Scheinberg DA, Jurcic JG. 2005. The promise of targeted α-particle therapy. J Nucl Med 46:199S-204S.
11. Chopp M, Dereski MO, Madigan L, Jiang F, Logie B. 1996. Sensitivity of 9L gliosarcomas to photodynamic therapy. Radiat Res 146:461-465.
12. Sun X, Leung WN. 2002. Photodynamic therapy with pyropheophorbide-a methyl ester in human lung carcinoma cancer cell: efficacy, localization and apoptosis. Photochem Photobiol 75:644-651.
13. Polo L, Reddi E, Garbo GM, Morgan AR, Jori G. 1992. The distribution of the tumour photosensitizers Zn(II)-phthalocyanine and Sn(IV)-etiopurpurin among rabbit plasma proteins. Cancer Lett 66:217-223.
14. Richter AM, Waterfield E, Jain AK, Canaan AJ, Allison BA, et al. 1993. Liposomal delivery of a photosensitizer, benzoporphyrin derivative monoacid ring A (bpd), to tumor tissue in a mouse tumor model. Photochem Photobiol 57:1000-1006.
15. Larroque C, Pelegrin A, van Lier JE. 1996. Serum albumin as a vehicle for zinc phthalocyanine: photodynamic activities in solid tumour models. Br J Cancer 74:1886-1890.
16. Scourides PA, Bohmer RM, Kaye AH, Morstyn G. 1987. Nature of the tumor-localizing components of hematoporphyrin derivative. Cancer Res 47:3439-3445.
17. Sobolev AS, Jans DA, Rosenkranz AA. 2000. Targeted intracellular delivery of photosensitizers. Prog Biophys Mol Biol 73:51-90.
18. Castano AP, Demidova TN, Hamblin MR. 2004. Mechanisms in photodynamic therapy: part one - photosensitizers, photochemistry and cellular localization. Photodiagnosis Photodynam Ther 1:279-293.
19. Kongshaug M. 1992. Distribution of tetrapyrrole photosensitizers among human plasma proteins. Int J Biochem 24:1239-1265.
20. Mori M, Kuroda T, Obana A, Sakata I, Hirano T, et al. 2000. In vitro plasma protein binding and cellular uptake of ATX-S10(Na), a hydrophilic chlorin photosensitizer. Jpn J Cancer Res 91:845-852.
21. Kubát P, Lang K, Anzenbacher P Jr. 2004. Modulation of porphyrin binding to serum albumin by pH. Biochim Biophys Acta 1670:40-48.
22. Bonneau S, Vever-Bizet C, Morliere P, Maziere JC, Brault D. 2002. Equilibrium and kinetic studies of the interactions of a porphyrin with low-density lipoproteins. Biophys J 83:3470-3481.
23. Rosenberger V, Margalit R. 1993. Thermodynamics of the binding of hematoporphyrin ester, a hematoporphyrin derivative-like photosensitizer, and its components to human serum albumin, human high-density lipoprotein and human low-density lipoprotein. Photochem Photobiol 58:627-630.
24. Gantchev TG, Ouellet R, van Lier JE. 1999. Binding interactions and conformational changes induced by sulfonated aluminum phthalocyanines in human serum albumin. Arch Biochem Biophys 366: 21-30.
25. Sasnouski S, Kachatkou D, Zorin V, Guillemin F, Bezdetnaya L. 2006. Redistribution of Foscan from plasma proteins to model membranes. Photochem Photobiol Sci 5:770-777.
26. Lang K, Mosinger J, Wagnerová DM. Photophysical properties of porphyrinoid sensitizers non-covalently bound to host molecules; models for photodynamic therapy 2004. Coordinat Chem Rev 248: 321-350.
27. Kessel D. 1989. Table I: Steady-state binding of dyes to plasma proteins. In: Bock G, Harnett S, editors. Photosensitizing Compunds: Their Chemistry, Biology and Clinical Use. Ciba Foundation Symp 146. Chichester: Wiley; 90 p.
28. Woodburn K, Kessel D. 1995. Effect of density-gradients on the binding of photosensitizing agents to plasma proteins. Int J Biochem Cell Biol 27:499-506.
29. Kongshaug M, Moan J, Rimington C, Evensen J. 1990. Binding of PDT photosensitizers to human plasma studied by ultracentrifugation, In: Kessel D, editor Photodynamic Therapy of Neoplastic Disease. Vol. II. New York: CRC Press; pp 43-62.
30. Kessel D, Thompson P, Saatio S, Nnantwi KD. 1987. Tumor localization and photosensitization by sulfonated derivatives of tetraphenylporphine. Photochem Photobiol 45:787-790.
31. Hopkinson HJ, Vernon DI, Brown SB. 1999. Identification and partial characterization of an unusual distribution of the photosensitizer metatetrahydroxyphenyl chlorin (temoporfin) in human plasma. Photochem Photobiol 69:482-488.
32. 6 in cancer patients. J Photochem Photobiol B 39:81-83.
33. Bellnier DA, Greco WR, Loewen GM, Nava H, Oseroff AR, et al. Population pharmacokinetics of the photodynamic therapy agent 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a in cancer patients 2003. Cancer Res 63:1806-1813.
34. Hastings RH, Wright JR, Albertine KH, Ciriales R, Matthay MA. 1994. Effect of endocytosis inhibitors on alveolar clearance of albumin, immunoglobulin g, and sp-a in rabbits. Am J Physiol 266:L544-L552.
35. Vorbrodt AW, Trowbridge RS. 1991. Ultrastructural study of transcellular transport of native and cationized albumin in cultured goat brain microvascular endothelium. J Neurocytol 20:998-1006.
36. Grant AJ, Jessup W, Dean RT. 1992 Accelerated endocytosis and incomplete catabolism of radical-damaged protein. Biochim Biophys Acta 1134:203-209.
37. Versluis AJ, van Geel PJ, Oppelaar H, van Berkel TJ, Bijsterbosch MK. 1996. Receptor-mediated uptake of low-density lipoprotein by B16 melanoma cells in vitro and in vivo in mice. Br J Cancer 74:525-532.
38. Schmidt U, Birngruber R, Hasan T. 1992. Selective occlusion of ocular neovascularization by photodynamic therapy. Ophthalmologie 89: 391-394.
39. Cozzani I, Jori G, Reddi E, Fortunato A, Granati B, et al. 1981. Distribution of endogenous and injected porphyrins at the subcellular level in rat hepatocytes and in ascites hepatoma. Chem Biol Interact 37:67-75.
40. Peng Q, Moan J, Nesland JM. 1996. Correlation of subcellular and intratumoral photosensitizer localization with ultrastructural features after photodynamic therapy. Ultrastruct Pathol 20:109-129.
41. Peng Q, Moan J, Farrants G, Danielsen HE, Rimington C. 1991. Localization of potent photosensitizers in human tumor lox by means of laser scanning microscopy. Cancer Lett 58:17-27.
42. Peng Q, Moan J, Farrants GW, Danielsen HE, Rimington C. 1991. Location of p-ii and alpcs4 in human tumor lox in vitro and in vivo by means of computer-enhanced video fluorescence microscopy. Cancer Lett 58:37-47.
43. Ruck A, Beck G, Bachor R, Akgun N, Gschwend MH, et al. 1996. Dynamic fluorescence changes during photodynamic therapy in vivo and in vitro of hydrophilic A1(III) phthalocyanine tetrasulphonate and lipophilic Zn(II) phthalocyanine administered in liposomes. J Photochem Photobiol B 36:127-133.
44. Rosenkranz AA, Jans DA, Sobolev AS. 2000. Targeted intracellular delivery of photosensitizers to enhance photodynamic efficiency. Immunol Cell Biol 78:452-464.
45. Sobolev AS, Akhlynina TV, Rosenkrants AA, Jans DA. 2002. Composition and method for causing photodynamic damage to target cells. US Patent #6,500,800.
46. 6 conjugate on human fibroblasts. Biull Eksp Biol Med USSR 109:150-152 [in Russian].
47. 6 for increasing its photosensitizing activity. Photochem Photobiol 58: 45-48.
48. Hamblin MR, Miller JL, Ortel B. 2000. Scavenger-receptor targeted photodynamic therapy Photochem Photobiol. 72:533-540.
49. Rosenkranz AA, Lunin VG, Gulak PV, Sergienko OV, Shumiantseva MA, et al. 2003. Recombinant modular transporters for cell-specific nuclear delivery of locally acting drugs enhance photosensitizer activity. FASEB J 17:1121-1123,
50. Rosenkranz AA, Lunin VG, Sergienko OV, Gilyazova DG, Shumiantseva MA, et al. 2003. Targeted intracellular site-specific drug delivery: Photosensitizer targeting to melanoma cell nuclei. Russ J Genetics 39: 259-268.
51. Gilyazova DG, Rosenkranz AA, Gulak PV, Lunin VG, Sergienko OV, et al. 2006. Targeting cancer cells by novel engineered modular transporters. Cancer Res 61:10534-10540.
52. Lokeshwar VB, Huang SS, Huang JS. 1989. Protamine enhances epidermal growth factor (EGF)-stimulated mitogenesis by increasing cell surface EGF receptor number. Implications for existence of cryptic EGF receptors. J Biol Chem 264:19318-19326.
53. Kawamoto T, Sato JD, Le A, Polikoff J, Sato GH, et al. 1983. Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an antireceptor monoclonal antibody. Proc Natl Acad Sci USA 80:1337-1341.
54. Nir S, Nieva JL. 2000. Interactions of peptides with liposomes: pore formation and fusion. Progr Lipid Res 39:181-206.
55. Ceresa BP, Schmid SL. 2000. Regulation of signal transduction by endocytosis. Curr Opin Cell Biol 12:204-210.
56. Catimel B, Teh T, Fontes MR, Jennings IG, Jans DA, et al. 2001. Biophysical characterization of interactions involving importin-α during nuclear import. J Biol Chem 276:34189-34198.
57. Hodel MR, Corbett AH, Hodel AE. 2001. Dissection of a nuclear localization signal. J Biol Chem 276:1317-1325.
58. Di Fiore PP, Pierce JH, Fleming TP, Hazan R, Ullrich A, et al. 1987. Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells. Cell 51:1063-1070.
59. Jiang J, Sharma SD, Fink JL, Hadley ME, Hruby VJ. 1996. Melanotropic peptide receptors: membrane markers of human melanoma cells. Exp Dermatol 5:325-333.
60. Funasaka Y, Sato H, Chakraborty AK, Ohashi A, Chrousos GP, Ichihashi M. 1999. Expression of proopiomelanocortin, corticotropin-releasing hormone (CRH), and CRH receptor in melanoma cells, nevus cells, and normal human melanocytes. J Investig Dermatol Symp Proc 4:105-109.
61. Wikberg JE, Muceniece R, Mandrika I, Prusis P, Lindblom J, et al. 2000. New aspects on the melanocortins and their receptors. Pharmacol Res 42:393-420.
62. Salazar-Onfray F, Lopez M, Lundqvist A, Aguirre A, Escobar A, et al. 2002. Tissue distribution and differential expression of melanocortin 1 receptor, a malignant melanoma marker. Br J Cancer 87:414-422.
63. Nizard P, Chenal A, Beaumelle B, Fourcade A, Gillet D. 2001. Prolonged display or rapid internalization of the IgG-binding protein ZZ anchored to the surface of cells using the diphtheria toxin T domain. Protein Eng 14:439-446.
64. Rosenkranz AA, Nabatnikov PA, Aliev RA, Jans DA, Sobolev AS. 2004. Enhancement of a cytotoxic effect by targeted transport of alpha-emitter Astatine-211 into human hepatoma cell nuclei. Molekulyarnaya Meditsina [Molecular Medicine, Moscow] 2:47-55 [in Russian].
65. Rosenkranz A, Vaidyanathan G, Pozzi O, Lunin V, Khramtsov Y, et al. 2007. Engineered modular transporters: An approach for targeted alpha particle radiotherapy. J Nucl Med 48:80P.
66. 211At. Nucl Med Biol 30:351-359.
67. 211At]astato- 2′-deoxyuridine, an α-particle emitting endoradiotherapeutic agent undergoing DNA incorporation. Cancer Res 56:204-1209.
68. Wikstrand CJ, Fung KM, Trojanowski JQ, McLendon RE, Bigner DD, 1998. Antibodies and molecular immunology: immunohistochemistry and antigens of diagnostic significance. In: Bigner DD, McLendon RE, Bruner JM, editors. Russell and Rubinstein's Pathology of the Nervous System, 6th edition. New York: Oxford University Press; pp 251-304.
69. Laskin JJ, Sandler AB. 2004. Epidermal growth factor receptor: a promising target in solid tumours. Cancer Treat Rev 30:1-17.
70. Brown SB, Brown EA, Walker I. 2004. The present and future role of photodynamic therapy in cancer treatment. Lancet Oncol 5:497-508.